Buy Albendazole

Albendazole

Albendazole: Generic Medication Overview

Albendazole is an antiparasitic medication belonging to the benzimidazole class. It is supplied as a 400 mg oral pill and is available in the United Kingdom only by prescription, regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). The tablet is typically packaged in blister packs and must be swallowed whole with water. Albendazole is indicated for the treatment of a range of helminthic infections, including neurocysticercosis, echinococcosis (hydatid disease), and several soil-transmitted intestinal worms.

How Albendazole Works in the Body

Albendazole exerts its antiparasitic effect by binding to β-tubulin in the parasite’s cells, which blocks the formation of microtubules. Without functional microtubules, parasites cannot uptake glucose and other nutrients, leading to a rapid depletion of their energy stores and eventual death. After oral administration, Albendazole is rapidly metabolised in the liver to albendazole sulfoxide, the pharmacologically active metabolite that circulates systemically and penetrates tissues, including the central nervous system. This property allows the drug to treat both intestinal and tissue-invasive parasites. Onset of action usually occurs within a few hours, with peak plasma concentrations of the sulfoxide metabolite reached 2-5 hours after a fatty meal.

Conditions Treated by Albendazole

• Neurocysticercosis (brain infection caused by Taenia solium cysts) - the most common cause of adult-onset epilepsy in endemic regions.
• Echinococcosis (hydatid disease) - cystic lesions of the liver, lungs, or other organs caused by Echinococcus granulosus or E. multilocularis.
• Soil-transmitted helminths such as:
• Ascaris lumbricoides (large roundworm)
• Trichuris trichiura (whipworm)
• Ancylostoma duodenale and Necator americanus (hookworms)
• Strongyloidiasis caused by Strongyloides stercoralis (particularly in disseminated disease).
• Filariasis (e.g., Wuchereria bancrofti) when used in combination with other antiparasitics.

These indications are approved by the MHRA and reflected in the UK Summary of Product Characteristics (SPC).

Off-Label and Investigational Applications

• Giardiasis - some clinical reports suggest Albendazole may be effective, but official guidelines (e.g., NICE) list metronidazole as first-line.
• Cutaneous larva migrans - Albendazole is used off-label in many countries; evidence consists of small case series.
• Toxocariasis - limited data support its use in visceral larva migrans, usually alongside corticosteroids.

Disclaimer: These uses are not approved by UK regulatory agencies. Off-label treatment must be prescribed and monitored by a qualified healthcare professional, with a clear risk-benefit assessment for each patient.

Who Should Not Use Albendazole?

Absolute Contraindications

• Known hypersensitivity to Albendazole or any benzimidazole derivative.
• Pregnancy during the first trimester (category D) - teratogenic risk documented in animal studies.
• Severe hepatic impairment (e.g., Child-Pugh C).

Relative Contraindications & Cautions

• Pregnancy after the first trimester - use only if potential benefits outweigh risks.
• Breast-feeding - Albendazole and its metabolite are excreted in milk; caution is advised.
• Children under 2 years of age - safety data are limited; dosing must be individually assessed.
• Pre-existing liver disease - baseline liver function tests are required and monitoring is essential.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Abdominal discomfort, nausea, or vomiting (typically mild and transient).
• Headache or dizziness.
• Transient elevation of liver enzymes (ALT, AST).
• Hair loss (alopecia) reported in prolonged therapy.
• Mild rash or pruritus.

Serious Adverse Events

• Hepatotoxicity - marked increase in transaminases, jaundice, or hepatic failure, especially with long-term courses.
• Bone-marrow suppression - neutropenia, leukopenia, or aplastic anemia; regular blood counts are advised for extended treatment.
• Severe allergic reactions - Stevens-Johnson syndrome, toxic epidermal necrolysis (very rare).
• Hypersensitivity anaphylaxis - immediate medical attention required.

Drug Interactions

• Cimetidine - increases Albendazole absorption; dose adjustment may be needed.
• Carbamazepine, Phenytoin, Rifampicin - potent inducers of hepatic enzymes; they can lower albendazole sulfoxide concentrations, potentially reducing efficacy.
• Warfarin - Albendazole may enhance anticoagulant effect; INR should be monitored closely.
• Antiretrovirals (e.g., efavirenz) - may alter metabolism; clinical judgment required.

Food and Lifestyle Interactions

• Fatty meals markedly improve oral absorption; patients are advised to take the tablet with food containing some fat.
• Alcohol should be limited, as concurrent hepatotoxic stress can increase liver-enzyme elevations.
• No known impact on driving or the use of machinery, but dizziness may occur in some individuals.

How to Take Albendazole

• Standard dosing for intestinal helminths: 400 mg as a single dose, repeated after 2-3 weeks if needed.
• Neurocysticercosis: 400 mg twice daily for 7-30 days, depending on disease burden and physician assessment.
• Echinococcosis (hydatid disease): 400 mg twice daily for 1-3 months, often combined with surgical intervention.

Note: Exact dosing schedules, treatment duration, and the need for repeat courses must be individualised by a healthcare provider based on infection type, severity, and patient characteristics.

Administration tips

• Swallow the pill whole with a full glass of water.
• Take the tablet with a fatty meal to maximise absorption.
• Do not crush, chew, or split the tablet unless explicitly instructed.

Missed dose

• If a dose is missed, take it as soon as remembered unless the next scheduled dose is within a few hours. Do not double-dose.

Overdose

• Symptoms may include severe nausea, vomiting, abdominal pain, and hepatic dysfunction. Seek emergency medical care; supportive treatment and monitoring of liver function are the mainstays.

Discontinuation

• For short courses, abrupt cessation is acceptable. For prolonged therapy (≥1 month), clinicians may monitor liver enzymes and blood counts before stopping; no tapering is required.

Monitoring and Follow-Up

• Baseline laboratory tests: liver function tests (ALT, AST, bilirubin) and a full blood count before initiating therapy, especially for courses longer than 7 days.
• During prolonged therapy (e.g., neurocysticercosis, hydatid disease): repeat liver function tests every 2 weeks and a complete blood count every 4 weeks.
• Clinical assessment: monitor for resolution of symptoms, emergence of adverse effects, and, where applicable, radiologic improvement (e.g., cyst size reduction).
• Pregnant patients: if treatment continues beyond the first trimester, fetal monitoring and specialist obstetric input are advised.

Storage and Handling

• Store the tablets at room temperature (≤ 30 °C), away from direct sunlight, moisture, and heat.
• Keep the medication out of reach of children; use child-proof containers.
• Do not use tablets that are past their expiry date or that appear discoloured or broken.
• Dispose of unused tablets according to local pharmacy take-back schemes or household waste guidelines if a take-back is unavailable.

Medication-Specific Glossary

Albendazole sulfoxide

The primary active metabolite formed in the liver; responsible for most of the drug’s systemic antiparasitic activity.

Microtubule inhibition

Disruption of the polymerisation of tubulin proteins, preventing formation of microtubules that parasites need for nutrient uptake and cellular structure.

Hepatotoxicity

Drug-induced liver injury, manifested by elevated liver enzymes, jaundice, or, in severe cases, liver failure.

Neurocysticercosis

Infection of the central nervous system by the larval cysts of the pork tapeworm (Taenia solium).

Cysticercosis (hydatid disease)

Disease caused by the larval stage of Echinococcus species, forming cysts primarily in the liver or lungs.

Medical Disclaimer

This article provides educational information about Albendazole and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.